Summary

Other Scenarios:

Buyer: Merck & Co., Inc. (MRK) Last Price: 50.73 Market Cap.: 109.95B
Target: MedImmune, Inc. (MEDI) Last Price: 57.94 Market Cap.: 13.84B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 884
Biopharmaceuticals 342
Scientific Products   39
Veterinary Products and Services   6
Manufacturing   1,185
Consumer Manufacturing   336

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 132)
  • Singulair (Montelukast Sodium)
  • Vytorin (Ezetimibe/Simvastatin)
  • Prinivil (Lisinopril)
  • Edecrin (Ethacrynic Acid)
Target (Total: 36)
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • MEDI-545 (Anti-Interferon Alpha Monoclonal Antibody)
  • MDX-1103 (Human Antibodies)
  • MEDI-546 (Anti-Type 1 Interferon Receptor Monoclonal Antibody)
Buyer
  • Rosetta Elucidator System
  • Rosetta Syllego System
  • Rosetta Resolver Systems
  • Merial Group Ltd.
Target

n/a

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 53)
  • Neurogen Corporation (NRGN)
  • Sunesis Pharmaceuticals, Inc. (SNSS)
  • Arena Pharmaceuticals, Inc. (ARNA)
  • Rigel Pharmaceuticals, Inc. (RIGL)
Target (Total: 17)
  • Micromet Inc. (MITI)
  • Infinity Pharmaceuticals Inc. (INFI)
  • Critical Therapeutics, Inc. (CRTX)
  • Option Care, Inc. (OPTN)
Buyer (Total: 8)
  • Bristol Myers Squibb Co. (BMY)
  • LG Philips LCD Co., Ltd. (ADR) (LPL)
  • AU Optronics Corp. (ADR) (AUO)
  • Sigma-Aldrich Corporation (SIAL)
Target (Total: 10)
  • AmerisourceBergen Corp. (ABC)
  • McKesson Corporation (MCK)
  • Cardinal Health, Inc. (CAH)
  • Abbott Laboratories (ABT)

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 60,000 2,359
Revenue Per Employee 385,683.3 976,913.8
Total Revenue 5,769.4 574.8
Total Expenses 3,515.0 342.4
Other Revenue 0.0 0.0
Cost of Revenue 1,525.8 115.5
SG&A Expense 1,802.0 147.1
Research & Development 1,030.0 79.5
Other Operating Expense -157.1 0.3
Operating Income 2,254.4 232.4
Unusual Income 65.8 0.0
LT Debt to Capital 23.08 44.29
Fwd P/E 17.14 64.37
Fwd P/Rev 4.69 9.51
Book Value 18,479.3 1,464.4
Curr Portion of LTD/Cap Lease 0.0 0.0

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals

Target

Focused (): *Healthcare > Biopharmaceuticals > Infectious Diseases > Viral

Business Description

Buyer

Merck & Co., Inc. (Merck) is a global pharmaceutical company that discovers, develops, manufactures and markets a range of products to improve human and animal health. The Company?s operations consist of two segments: the Pharmaceutical segment and the Vaccines segment. The Pharmaceutical segment includes human health pharmaceutical products marketed either directly or through joint ventures. The Vaccines segment includes human health vaccine products marketed either directly or through a joint venture. During the year ended December 31, 2006, five products of Merck received the United States Food and Drug Administration (FDA) approval: Gardasil (Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine), Januvia (sitagliptin phosphate), Zostavax, RotaTeq and Zolinza. In 2006, Merck acquired Abmaxis, Inc,. GlycoFi, Inc., Sirna Therapeutics, Inc. and a 11% stake in FoxHollow Technologies, Inc.

Target

MedImmune, Inc. is a biotechnology company focusing its efforts on the therapeutic areas of infectious disease, cancer and inflammatory disease. The Company primarily develops monoclonal antibodies and vaccines. MedImmune markets three products: Synagis (palivizumab) and FluMist (Influenza Virus Vaccine Live, Intranasal) to help prevent two common respiratory infectious diseases, and Ethyol (amifostine) to help reduce adverse side effects of certain anti-cancer chemotherapies and radiotherapies. The Company is also developing a pipeline of product candidates for potential commercialization. MedImmune operates facilities in the United States and Europe to manufacture and distribute one or more components of each of its products. The Company has established clinical, research, development, manufacturing and commercialization collaborations with other companies and organizations. In December 2006, MedImmune sold all rights to the CytoGam product line and related assets to ZLB Behring AG.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 73.11 76.35
Operating Margin % 28.29 11.19
Quick Ratio 1.03 3.64
Current Ratio 1.49 3.98
Coverage Ratio 0 0.61
Total Assets 42,992.5 3,033.5
Return on Equity % 24.99 11.04
Return on Assets % 10.74 5.33
Cash+ ST Inv. Per Share 1.86 4.3
Total Debt 6,476.0 1,164.1
Total Debt to Equity % 35.04 79.49
Total Debt to Tangible Equity % 40.07 91.37
Debt to Asset % 15.06 38.37

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
  
Scientific Products  
Analytical Instruments
The Analytical Instruments Subsector includes scientific products that determine the quantitative and qualitative nature of biochemical samples.
  
Bioanalytical Instruments
The Bioanalytical Instruments Subsector includes scientific products, devices and apparatuses that determine the quantitative and qualitative nature of a biological samples.
  
Veterinary Products and Services  
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.

Buyer Products:

  • Merial Group Ltd.
  
Veterinary Services
The Veterinary Services Subsector includes companies that diagnose and treat animal diseases, such as veterinary laboratories, clinics, and hospitals.

Buyer Products:

  • Merial Group Ltd.
  
Manufacturing  
Consumer Manufacturing  
Food, Beverage and Agriculture
Includes agricultural inputs like livestock and crops, as well as processed food and beverage products. Tobacco growers and cigarette manufacturers are also included.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies  
Upper Respiratory  
Leukotriene Receptor Antagonists
Therapeutics that treat allergic reactions by working on certain receptors involved in the immune process.

Buyer Products:

  • Singulair (Montelukast Sodium)
  
Cardiovascular System  
Heart Disorders  
Acute Coronary Syndrome (ACS)  
Cholesterol Absorption Inhibitors (CETP)/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that reduce the incidence of acute coronary syndrome (ACS) by blocking cholesterol synthesis and also inhibiting the absorption of cholesterol.

Buyer Products:

  • Vytorin (Ezetimibe/Simvastatin)
  
Heart Failure (HF)  
Adjunctive Treatments  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that assist in the primary treatment of the ineffective pumping of the heart by inhibiting the renin-angiotensin system.

Buyer Products:

  • Prinivil (Lisinopril)
  
Complications  
Edema  
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Edecrin (Ethacrynic Acid)
  
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.

Buyer Products:

  • Diuril (Chlorathiazide Sodium)
  
Myocardial Infarction (MI)  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the renin-angiotensin system.

Buyer Products:

  • Prinivil (Lisinopril)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MK-0724
  • MK-6213
  • MK-0448
  • MK-8141
  • MK-0859
  • MK-0633
  • MK-0736
  
Vascular Disorders  
Atherosclerosis  
Free Fatty Acid Inhibitors/Prostaglandin Inhibitors  
Free Fatty Acid Inhibitors/Prostaglandin Inhibitors/Statins  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.

Buyer Products:

  • Mevacor (Lovastatin)
  
Coronary Artery Disease (CAD)  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by preventing the synthesis of cholesterol.

Buyer Products:

  • Zocor (Simvastatin)
  
Hypertension  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.

Buyer Products:

  • Prinivil (Lisinopril)
  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Prinzide (Lisinopril/Hydrochlorothiazide)
  
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.

Buyer Products:

  • Cozaar (Losartan Potassium)
  
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Hyzaar (Losartan Potassium/Hydrochlorothiazide)
  
Stroke  
Angiotensin II Receptor Antagonists
Therapeutics that reduce the risk of stroke by reducing high blood pressure through blocking the angiotensin II receptor.

Buyer Products:

  • Cozaar (Losartan Potassium)
  
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that reduce the risk of stroke by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Hyzaar (Losartan Potassium/Hydrochlorothiazide)
  
Dermatology
Hair Disorders  
Alopecia (Hair Loss)  
5 Alpha Reductase Inhibitors
Therapeutics that treat hair loss by blocking the action of an enzyme that converts testosterone to a testosterone derivative.

Buyer Products:

  • Propecia (Finasteride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.

Target Products:

  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • MEDI-545 (Anti-Interferon Alpha Monoclonal Antibody)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Sirna Therapeutics RNA Interference (RNAi) Technology
  
Digestive System  
Gastrointestinal Tract Disorders  
Gastroduodenal Disorders  
Peptic Ulcers  
Duodenal  
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Pepcid Complete (Famotidine, Calcium Carbonate, Magnesium Hydroxide)
  • Pepcid (Famotidine)
  
Gastric  
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Pepcid Complete (Famotidine, Calcium Carbonate, Magnesium Hydroxide)
  • Pepcid (Famotidine)
  
Zollinger-Ellison Syndrome  
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Pepcid (Famotidine)
  
Gastroesophageal Disorders  
Abdominal Gas  
Acid Neutralizing Agents/Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the acidity of the stomach as well as lowering the surface tension of gas bubbles in the bowels.

Buyer Products:

  • Pepcid Complete (Famotidine, Calcium Carbonate, Magnesium Hydroxide)
  • Fast-Acting Mylanta (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone)
  
Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the surface tension of gas bubbles in the bowels.

Buyer Products:

  • Infants' Mylicon (Simethicone)
  • Pepcid Complete (Famotidine, Calcium Carbonate, Magnesium Hydroxide)
  • Mylanta Gas (Simethicone) Series
  
Acid Indigestion/Heartburn  
Acid Neutralizing Agents
Therapeutics that treat heartburn by neutralizing stomach acid.

Buyer Products:

  • Pepcid Complete (Famotidine, Calcium Carbonate, Magnesium Hydroxide)
  • Mylanta Gelcaps (Calcium Carbonate/Magnesium Hydroxide)
  • Fast-Acting Mylanta (Calcium Carbonate/Magnesium Hydroxide)
  • Children's Mylanta (Calcium Carbonate)
  
Acid Neutralizing Agents/Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat indigestion by neutralizing the stomach acid as well as lowering the surface tension of the gas bubbles in the bowels.

Buyer Products:

  • Pepcid Complete (Famotidine, Calcium Carbonate, Magnesium Hydroxide)
  • Fast-Acting Mylanta (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone)
  
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.

Buyer Products:

  • Pepcid AC (Famotidine)
  • Pepcid Complete (Famotidine, Calcium Carbonate, Magnesium Hydroxide)
  
Gastroesophageal Reflux Disease (GERD)  
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.

Buyer Products:

  • Pepcid (Famotidine)
  • Pepcid Complete (Famotidine, Calcium Carbonate, Magnesium Hydroxide)
  
Nausea/Vomiting  
Neurokinin-1 (NK-1) Receptor Antagonists
Therapeutics that prevent or treat nausea and vomiting by inhibiting the neurotransmitter NK-1 (Substance P) from binding to its receptors.

Buyer Products:

  • Emend For Injection (Intravenous Aprepitant)/Formerly MK-0517
  • Emend (Aprepitant)
  
Liver Disorders  
Cirrhosis  
Complications  
Edema  
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Edecrin (Ethacrynic Acid)
  
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.

Buyer Products:

  • Diuril (Chlorathiazide Sodium)
  
Wilson`s Disease  
Chelating Agents
Therapeutics that treat Wilson's Disease by binding to and removing copper.

Buyer Products:

  • Syprine (Trientine Hydrochloride)
  • Cuprimine (Penicillamine)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MK-0608
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Sirna-034
  
Endocrinology/Metabolism  
Diabetes  
Induced Complications  
Nephropathy  
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disese by blocking the angiotensin II receptor.

Buyer Products:

  • Cozaar (Losartan Potassium)
  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes  
Biguanides/Dipeptidyl Peptidase (DPP) Inhibitors
Therapeutics that control high blood sugar by stimulating the release of insulin and by modifying gastric emptying, insulin secretion, and glucagon secretion.

Buyer Products:

  • JANUMET (Sitagliptin phosphate/Metformin)
  
Dipeptidyl Peptidase (DPP) Inhibitors
Therapeutics that treat non-insulin dependent diabetes by inhibiting the action of dipeptidyl peptidase, thereby increasing the level of glucagon-like peptide-1 (GLP-1). GLP regulates gastric emptying, insulin secretion, food intake, and glucagon secretion.

Buyer Products:

  • Januvia (Sitagliptin Phosphate)
  
Intermediary Metabolism Disorders  
Gout  
Gouty Arthritis  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by selectively blocking cyclooxygenase 2.

Buyer Products:

  • Arcoxia (Etoricoxib/MK-663)
  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation preventing cyclooxygenase activity.

Buyer Products:

  • Indocin (Indomethacin)
  • Clinoril (Sulindac)
  
Hypercholesterolemia  
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive cholesterol level by inhibiting the absorption of cholesterol.

Buyer Products:

  • Zetia (Ezetimibe)
  
Cholesterol Absorption Inhibitors (CETP)/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hypercholesterolemia through the dual action of blocking cholesterol synthesis by binding a key enzyme in the synthesis process and also inhibiting the absorption of cholesterol.

Buyer Products:

  • Vytorin (Ezetimibe/Simvastatin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Mevacor (Lovastatin)
  • Zocor (Simvastatin)
  
Hyperlipidemia  
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive triglyceride level by inhibiting the absorption of cholesterol.

Buyer Products:

  • Zetia (Ezetimibe)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Zocor (Simvastatin)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MK-0893
  • MK-0677
  • MK-0941
  • MK-3887
  • MK-1642
  • MK-0974 (CGRP Receptor Antagonist)
  • MK-0533
  • Zetia (Ezetimibe)/Atorvastatin Combination Product
  • MK-0867
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Sirna Therapeutics RNA Interference (RNAi) Technology
  
Hematology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Zetia (Ezetimibe)/Atorvastatin Combination Product
  
Serum Factor Disorders  
Hypercholesterolemia  
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive cholesterol level by inhibiting the absorption of cholesterol.

Buyer Products:

  • Zetia (Ezetimibe)
  
Cholesterol Absorption Inhibitors/HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat hypercholesterolemia through the dual action of blocking cholesterol synthesis by binding a key enzyme in the synthesis process and also inhibiting the absorption of cholesterol.

Buyer Products:

  • Vytorin (Ezetimibe/Simvastatin)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Zocor (Simvastatin)
  • Mevacor (Lovastatin)
  
Hyperlipidemia  
Cholesterol Absorption Inhibitors
Therapeutics that treat excessive triglyceride level by inhibiting the absorption of cholesterol.

Buyer Products:

  • Zetia (Ezetimibe)
  
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.

Buyer Products:

  • Zocor (Simvastatin)
  
Thrombocyte (Platelet) Disorders  
Hypoprothrombinemia  
Vitamin K Analogs
Therapeutics that treat the deficiency of coagulation factor II.

Buyer Products:

  • Mephyton (Phytonadione)
  
Immunology
Autoimmune Disorders  
Arthritis  
Rheumatoid Arthritis (RA)  
Analgesics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.

Buyer Products:

  • Vioxx (Rofecoxib)
  • Arcoxia (Etoricoxib/MK-663)
  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.

Buyer Products:

  • Clinoril (Sulindac)
  • Indocin (Indomethacin)
  
Immunotherapy  
Chelating Agents
Therapeutics that treat rheumatoid arthritis by lowering IgM rheumatoid factor and depressing T-cell activity.

Buyer Products:

  • Cuprimine (Penicillamine)
  
Immune Deficiency Disorders  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Integrase Inhibitors
Therapeutics that help manage HIV by blocking the integration of the HIV virus' genetic material into the host cell.

Buyer Products:

  • Isentress (Raltegravir)/Formely MK-0518
  
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.

Buyer Products:

  • Crixivan (Indinavir Sulfate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • V526

Target Products:

  • MEDI-545 (Anti-Interferon Alpha Monoclonal Antibody)
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in very early stages of research where no human subject is involved.

Target Products:

  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • MDX-1103 (Human Antibodies)
  • MEDI-546 (Anti-Type 1 Interferon Receptor Monoclonal Antibody)
  • Anti-Chitinase MAb
  • Anti-CD19/Anti-CD20/Anti-CD22 Monoclonal Antibodies
  • Anti-HMGB1 Monoclonal Antibody
  • Anti-ICOS MAbs
  
Infectious Diseases
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Carbapenems
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Primaxin (Imipenem/Cilastatin)
  • Invanz (Ertapenem Sodium)
  
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Mefoxin (Cefoxitin Sodium)
  
Quinolones/Fluoroquinolones
Therapeutics that treat a wide variety of infections by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Noroxin (Norfloxacin)
  
Vaccines  
Bacterial  
Single Target  
Haemophilus Influenzae Type B (Hib)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause Haemophilus influenzae type B.

Buyer Products:

  • Pedvax HIB (Haemophilus b Conjugate Vaccine/Meningococcal Protein Protein Conjugate)
  
Streptococcus pneumoniae
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause pneumococcal bacteria.

Buyer Products:

  • Pneumovax 23 (Pneumococcal Vaccine Polyvalent)
  
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial or viral pathogen.

Buyer Products:

  • Comvax (Haemophilus Influenza B Conjugate And Hepatitis B Vaccine)
  
Helminthic  
Cutaneous Larva Migrans (Creeping Eruptions)  
Antimicrotubule Agents
Therapeutics that treat parasitic infections of the skin caused by the dog and cat hookworm.

Buyer Products:

  • Mintezol (Thiabendazole)
  
Onchocerciasis (River Blindness)  
Gamma-Aminobutyric Acid (GABA) Agonists
Therapeutics that treat parasitic infections characterize by worm filled nodules under the skin and itching.

Buyer Products:

  • Stromectol (Ivermectin)
  
Strongyloidiasis (Threadworm)  
Antimicrotubule Agents
Therapeutics that treat helminthic infections by disrupting the cell cycle of the worm.

Buyer Products:

  • Mintezol (Thiabendazole)
  
Gamma-Aminobutyric Acid (GABA) Agonists
Therapeutics that treat parasitic infections of the intestines leading to mild to severe diarrhea.

Buyer Products:

  • Stromectol (Ivermectin)
  
Trichinosis  
Antimicrotubule Agents
Therapeutics that treat parasitic infections of the tissues and intestines caused by consuming infected meat.

Buyer Products:

  • Mintezol (Thiabendazole)
  
Visceral Larval Migrans  
Antimicrotubule Agents
Therapeutics that treat parasitic infections caused by the migration of an organism to the extraintestinal tissue.

Buyer Products:

  • Mintezol (Thiabendazole)
  
Mycological (Fungal)
Antifungal Agents
Broad Spectrum  
Echinocandins
Therapeutics that treat fungal infections by inhibiting the synthesis of a major cell wall component.

Buyer Products:

  • Cancidas (Caspofungin Acetate)
  
Narrow Spectrum
Digestive System  
Mucous  
Candidiasis  
Echinocandins
Therapeutics that treat fungal infections due to candidiasis through a broad spectrum fungicidal action.

Buyer Products:

  • Cancidas (Caspofungin Acetate)
  
Respiratory System  
Pneumocystis Carinii Pneumonia (PCP)  
Dihydrofolate Reductase Inhibitors
Therapeutics that treat infections of the lungs of immunocompromised patients caused by Pneumocystis carinii by blocking the action of dihydrofolate reductase.

Target Products:

  • Neutrexin (Trimetrexate Glucuronate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • V502 HPV Vaccine
  • MK-0608
  • V710 S. Aureus Vaccine
  • MK-7009
  • MK-8122
  • V526
  • V512 Influenza Vaccine

Target Products:

  • RSV/Anti-Human Metapneumovirus (hMPV)/Parainfluenzavirus (PIV) Vaccine
  • Anti-Human Metapneumovirus Monoclonal Antibody
  • RSV Vaccine
  • Epstein-Barr Virus (EBV) Vaccine
  • Streptococcus pneumoniae Vaccine
  • Intranasal H5N1 Influenza Vaccine
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • Sirna-034

Target Products:

  • EphA2 Antagonists
  • Streptococcus pneumoniae Vaccine
  • Anti-Candida HP Monoclonal Antibody
  • Anti-Staphylococcal HP Monoclonal Antibody
  • Anti-RSV Drug
  • Third Generation Respiratory Syncitial Virus (RSV) Monoclonal Antibody
  • Anti-HMGB1 Monoclonal Antibody
Viral
RNA Viruses
Paramyxovirus  
Respiratory Syncytial Virus (RSV)  
Immunoglobulins
Therapeutics that treat viral infections in the respiratory tracts of infants with a variety of specific protein that neutralizes the virus.

Target Products:

  • RespiGam (Respiratory Syncytial Virus Immune Globulin Intravenous)
  
Monoclonal Antibodies
Therapeutics that treat viral infections in the respiratory tracts of infants with a neutralizing protein that targets a specific site on the virus.

Target Products:

  • Numax (Anti-RSV MAb)
  • Synagis (Palivizumab)
  • Liquid Synagis (Palivizumab)
  
Retrovirus  
Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)  
Integrase inhibitors
Therapeutics that help manage HIV by blocking the integration of the HIV virus' genetic material into the host cell.

Buyer Products:

  • Isentress (Raltegravir)/Formely MK-0518
  
Protease Inhibitors
Therapeutics that help manage HIV by binding to and blocking the action of HIV protease, an enzyme necessary for viral replication.

Buyer Products:

  • Crixivan (Indinavir Sulfate)
  
Vaccines
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial and viral pathogens.

Buyer Products:

  • Comvax (Haemophilus Influenza B Conjugate And Hepatitis B Vaccine)
  
Viral
Combination  
Measles/Mumps/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles, mumps, and rubella.

Buyer Products:

  • M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live)
  
Measles/Mumps/Rubella/Varicella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles, mumps, rubella, and varicella.

Buyer Products:

  • Proquad (Chickenpox, Measles, Mumps, Rubella Vaccine)
  
Measles/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles and rubella. .

Buyer Products:

  • M-R-Vax II (Measles And Rubella Virus Vaccine Live)
  
Mumps/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to mumps and rubella.

Buyer Products:

  • Biavax II (Rubella And Mumps Virus Vaccine)
  
Single Target
Hepatitis A
Therapeutics that prevent or treat viral infections of the liver by producing or artificially increasing immunity to the Hepatitis A virus.

Buyer Products:

  • Vaqta (Hepatitis A Vaccine, Inactivated)
  
Hepatitis B
Therapeutics that prevent or treat viral infections of the liver by producing or artificially increasing immunity to the Hepatitis B virus.

Buyer Products:

  • Recombivax HB (Recombinant Hepatitis B Vaccine)
  
Herpes Zoster (Shingles)
Therapeutics that prevent or treat viral infections that cause shingles in adults.

Buyer Products:

  • Zostavax
  
Influenza (Flu)
Therapeutics that prevent or treat viral infections of the respiratory tract by producing or artificially increasing immunity to the Influenza virus.

Target Products:

  • FluMist (Influenza Virus Vaccine Live, Intranasal)
  • FluMist Refrigerated Formualtion (Influenza Vaccine Live, Intranasal)
  
Measles
Therapeutics that prevent or treat viral infections characterized by a red rash by producing or artificially increasing immunity to the measles virus.

Buyer Products:

  • Attenuvax (Measles Virus Vaccine Live)
  
Mumps
Therapeutics that prevent or treat viral infections characterized by swelling of salivary glands below the ear by producing or artificially increasing immunity to the mumps virus.

Buyer Products:

  • Mumpsvax (Mumps Virus Vaccine Live)
  
Papillomavirus
Therapeutics that prevent or treat viral infections characterized by the proliferation of epithelial cells, leading to the formation of warts and possibly other related diseases such as cervical pre-cancers and cervical cancer.

Buyer Products:

  • Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)
  
Rotavirus
Therapeutics that prevent or treat viral infections that cause severe dehydrating diarrhea in children by producing or artificially increasing immunity to the rotavirus.

Buyer Products:

  • Rotateq
  
Rubella (German Measles)
Therapeutics that prevent or treat viral infections that begin in the lower respiratory tract and lead to a rash by producing or artificially increasing immunity to the rubella virus.

Buyer Products:

  • Meruvax II (Rubella Virus Vaccine Live)
  
Varicella-Zoster Virus (Chicken Pox)
Therapeutics that prevent or treat viral infections that cause a blistery red rash by producing or artificially increasing immunity to the Varicella Zoster virus.

Buyer Products:

  • Varivax (Varicella Virus Vaccine Live)
  
Musculoskeletal System
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MK-0773
  • MK-0822
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in very early stages of research where no human subject is involved.

Target Products:

  • Anti-HMGB1 Monoclonal Antibody
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  
Skeletal Disorders  
Bone Disorders  
Osteoporosis  
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.

Buyer Products:

  • Fosamax (Alendronate Sodium)
  
Osteoclast Bone Resorption Inhibitors/Vitamin D Analogs
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts and by increasing calcium absorption.

Buyer Products:

  • Fosamax Plus D (Alendronate Sodium/Cholecalciferol)
  
Paget`s Disease  
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.

Buyer Products:

  • Fosamax (Alendronate Sodium)
  
Joint Disorders  
Ankylosing Spondylitis  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Indocin (Indomethacin)
  • Clinoril (Sulindac)
  
Gouty Arthritis  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by selectively blocking cyclooxygenase 2.

Buyer Products:

  • Arcoxia (Etoricoxib/MK-663)
  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.

Buyer Products:

  • Indocin (Indomethacin)
  • Clinoril (Sulindac)
  
Osteoarthritis (OA)  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.

Buyer Products:

  • Vioxx (Rofecoxib)
  • Arcoxia (Etoricoxib/MK-663)
  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Indocin (Indomethacin)
  • Clinoril (Sulindac)
  
Rheumatoid Arthritis (RA)  
Analgesics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.

Buyer Products:

  • Vioxx (Rofecoxib)
  • Arcoxia (Etoricoxib/MK-663)
  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.

Buyer Products:

  • Indocin (Indomethacin)
  • Clinoril (Sulindac)
  
Immunotherapy  
Chelating Agents
Therapeutics that treat rheumatoid arthritis by lowering IgM rheumatoid factor and depressing T-cell activity.

Buyer Products:

  • Cuprimine (Penicillamine)
  
Neurology  
Neurological Disorders  
Headaches  
Vascular (Migraine)  
Acute Treatments  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat acute migraine by selectively blocking cyclooxygenase 2 activity.

Buyer Products:

  • Vioxx (Rofecoxib)
  
Selective Serotonin Receptor Agonists (Triptans)
Therapeutics that treat vascular/migraine headaches by stimulating the receptor that binds with the neurotransmitter, serotonin.

Buyer Products:

  • Maxalt (Rizatriptan Benzoate)
  
Neuromuscular Disorders  
Parkinson`s Disease (PD)  
Adjunctive Treatments  
Dopamine Receptor Agonists
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by stimulating dopamine receptors on neurons.

Buyer Products:

  • Sinemet (Carbidopa/Levodopa)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MK-2637
  • MK-0657
  • MK-0952
  • MK-5757
  • MK-0249
  • MK-0454
  • MK-8998
  • MK-0974 (CGRP Receptor Antagonist)
  
Psychiatric Disorders  
Mood Disorders  
Depression  
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.

Buyer Products:

  • Vivactil (Protriptyline Hydrochloride)
  
Sleep Disorders  
Insomnia  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.

Buyer Products:

  • Gaboxadol
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Sirna Therapeutics RNA Interference (RNAi) Technology
  
Oncology
Endocrinology  
Adrenal Glands  
Pheochromocytoma  
Tyrosine Hydroxylase Inhibitors
Therapeutics that treat adrenal gland tumors that produce epinephrine and norepinephrine by inhibiting the production of epinephrine and norepinephrine.

Buyer Products:

  • DEMSER (Metyrosine)
  
Head/Neck Cancer  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treament for head and neck cancers.

Target Products:

  • Ethyol (Amifostine)
  
Hematology  
Leukemia (White Blood Cell Cancer)  
Lymphoid  
Acute  
Lymphocytic  
Asparaginases
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by breaking down asparagine which is necessary for cell survival.

Buyer Products:

  • ELSPAR (Asparaginase)
  
Palliative Agents  
Alkylating Agents  
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage cancers of myeliod cells by interacting with DNA and inhibiting cell division but are not curative.

Buyer Products:

  • Mustargen (Mechlorethamine HCL)
  
Lymphoma (Lymphatic Cancer)  
Cutaneous T-Cell (CTCL)  
Mycosis Fungoides  
Alkylating Agents  
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage T-Cell lymphomas of the skin by interacting with DNA and inhibiting cell division.

Buyer Products:

  • Mustargen (Mechlorethamine HCL)
  
Histone Deacetylase (HDAC) Inhibitors
Therapeutics that treat and manage T-Cell lymphomas of the skin by inhibiting deacetylation of histone, leading to expression of genes responsible for tumor growth regulation and apoptosis.

Buyer Products:

  • Zolinza (Vorinostat)
  
Hodgkin`s Disease  
Palliative Agents  
Alkylating Agents  
Nitrogen Mustard Type
Therapeutics derived from mustard gas that treat and manage lymphoma characterized by the presence of Reed-Sternberg cells by interacting with DNA and inhibiting cell division but that are not curative.

Buyer Products:

  • Mustargen (Mechlorethamine HCL)
  
Musculoskeletal System  
Bone Cancer  
Ewing`s Sarcoma (Primitive Neuroepithelial Cancer)  
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat Ewing's Sarcoma by interacting with DNA.

Buyer Products:

  • Cosmegen (Dactinomycin)
  
Rhabdomyosarcoma  
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat and manage cancers arising from striated muscle by interacting with DNA.

Buyer Products:

  • Cosmegen (Dactinomycin)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • MK-0731
  • MK-0646
  • MK-0457/VX-680 (Aurora Kinase Inhibitor)
  • MK-6592/VX-667
  • MK-0429
  • MK-0752
  • MK-0822
  • MK-4721
  • V930 Cancer Vaccine
  • V502 HPV Vaccine

Target Products:

  • MT103/MEDI-538 (T-Cell Engager)
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • Intravenous IPI-504 (Hsp90 inhibitor)
  • Ethyol (Amifostine)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • VX-689 ( Aurora Kinase Inhibitor)

Target Products:

  • Anti-EphB4/Anti-EphrinB2 Antibodies
  • cMET Receptor Antagonists
  • EphA4 Agonists
  • Anti-CD19/Anti-CD20/Anti-CD22 Monoclonal Antibodies
  • Anti-ALK Monoclonal Antibody
  • EphA2 Antagonists
  • Siplizumab (Monoclonal Antibody - Formerly MEDI-507)
  • Hedgehog Antagonist
  • Anti-Chitinase MAb
Respiratory System/Thoracic  
Lung Cancer  
Non Small Cell Lung Cancer (NSCLC)  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treatment for cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma

Target Products:

  • Ethyol (Amifostine)
  
Urology
Cervical Cancer  
Localized  
Papillomavirus Vaccines
Therapeutics that are meant to promote an immune response against the Papillomavirus that are involved in the pathogenesis of cervical cancer.

Buyer Products:

  • Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)
  
Kidney Cancer (Renal Cell Carcinoma)  
Wilm`s Tumor (Nephroblastoma)  
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat kidney cancer by interacting with DNA.

Buyer Products:

  • Cosmegen (Dactinomycin)
  
Ovarian Cancer  
Palliative Agents  
Thiophosphate Cytoprotective Agents
Therapeutics that treat nephropathy associated with repeated cisplatin treatment for cancers of the ovaries.

Target Products:

  • Ethyol (Amifostine)
  
Testicular Cancer  
Metastatic  
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat testicular cancers that have spread beyond their original tumor site by interacting with DNA.

Buyer Products:

  • Cosmegen (Dactinomycin)
  
Uterine Cancer  
Antitumor Antibiotics
Therapeutics isolated principally from microorganisms that treat cancer of the uteris by interacting with DNA.

Buyer Products:

  • Cosmegen (Dactinomycin)
  
Vulvar Cancer  
Squamous Cell Carcinoma  
Papillomavirus Vaccines
Therapeutics that promote an immune response against the Papillomavirus that are involved in the pathogenesis of vaginal and vulvar cancers.

Buyer Products:

  • Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)
  
Ophthalmology  
Degenerative Disorders  
Dry Eye  
Lubricants
Therapeutics that wet the eye and lubricate the eye.

Buyer Products:

  • Lacrisert (Hydroxypropyl Cellulose)
  
Glaucoma  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that decrease the formation of the fluid of the eye.

Buyer Products:

  • Timoptic (Timolol Maleate)
  
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.

Buyer Products:

  • Trusopt (Dorzolamide Hydrochloride)
  
Carbonic Anhydrase Inhibitors/Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that decrease the formation of the fluid of the eye.

Buyer Products:

  • Cosopt (Dorzolamide Hydrochloride/Timolol Maleate)
  
Ocular Hypertension  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that decrease the formation of the fluid of the eye.

Buyer Products:

  • Timoptic (Timolol Maleate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MK-0994
  • Sirna-027
  
Pain Management  
Non-Narcotics  
Non-Steroidal Anti-Inflammatory Drugs (NSAID)  
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.

Buyer Products:

  • Arcoxia (Etoricoxib/MK-663)
  • Vioxx (Rofecoxib)
  
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.

Buyer Products:

  • Clinoril (Sulindac)
  • Indocin (Indomethacin)
  
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.

Buyer Products:

  • Flexeril (Cyclobenzaprine HCL)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Buyer Products:

  • NGD-8243/MK-2295 (Vanilloid Receptor-1 Modulator)
  • MK-6721
  • MK-0759
  
Respiratory System
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Prophylactic Treatments  
Leukotriene Receptor Antagonists
Therapeutics that treat asthma by reducing inflammation in the lung passages by working on certain receptors involved in the immune process.

Buyer Products:

  • Singulair (Montelukast Sodium)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MK-0633
  • NGD-8243/MK-2295 (Vanilloid Receptor-1 Modulator)

Target Products:

  • BIW-8405 (IL-5 Monoclonal Antibody)
  • MEDI-528 (IL-9 Monoclonal Antibody)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • Sirna Therapeutics RNA Interference (RNAi) Technology
  
Surgery  
Oncology  
Endocrinology  
Adrenal Glands  
Tyrosine Hydroxylase Inhibitors
Therapeutics that are used prior to specific surgical procedures to remove high levels of epinephrine and norepinephrine.

Buyer Products:

  • DEMSER (Metyrosine)
  
Urology  
Male Genital Disorders  
Prostate  
Benign Prostate Hyperplasia (BPH)  
5-Alpha Reductase Inhibitors
Therapeutics that inhibit the transformation of testosterone into dihydrotestosterone (DHT), a substance that causes enlargement of the prostate.

Buyer Products:

  • Proscar (Finasteride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • NGD-8243/MK-2295 (Vanilloid Receptor-1 Modulator)
  • MK-0634
  • MK-0594
  
Urological Disorders  
Bladder  
Neurogenic Bladder Disease  
Cholinergic Agents
Therapeutics that treat bladder dysfunction arising from the malfunction of autonomic nerves that control bladder function with choleinergic agents.

Buyer Products:

  • Urecholine (Bethanechol Chloride)
  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Edema  
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.

Buyer Products:

  • Edecrin (Ethacrynic Acid)
  
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.

Buyer Products:

  • Diuril (Chlorathiazide Sodium)
  
Cystinuria  
Chelating Agents
Therapeutics that treat an inherited abnormality of kidney function which results in increased excretion of certain amino acids by forming complexes with these amino acids to decrease their excretion.

Buyer Products:

  • Cuprimine (Penicillamine)
  
Diabetic Nephropathy  
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disese by blocking the angiotensin II receptor.

Buyer Products:

  • Cozaar (Losartan Potassium)
  
Weight Management  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MK-0364 (Taranabant)
  
Wound Management  
Ulcers  
Diabetic Foot  
Carbapenems
Therapeutics that treat foot ulcers by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Invanz (Ertapenem Sodium)
  
Scientific Products  
Analytical Instruments  
Chromatography  
Software
Software designed to facilitate the function and control of liquid chromatography machines.

Buyer Products:

  • Rosetta Elucidator System
  
Bioanalytical Instruments  
Biomolecular  
Microarray Technology  
Software
Computer programs specified for microarray/biochip technology systems used in the analysis of samples.

Buyer Products:

  • Rosetta Syllego System
  • Rosetta Resolver Systems
  
Veterinary Products and Services  
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.

Buyer Products:

  • Merial Group Ltd.
  
Veterinary Services
The Veterinary Services Subsector includes companies that diagnose and treat animal diseases, such as veterinary laboratories, clinics, and hospitals.

Buyer Products:

  • Merial Group Ltd.
  
Manufacturing  
Consumer Manufacturing  
Food, Beverage and Agriculture  
Agriculture  
Animal Production  
Support Activities for Animal Production
Includes food irradiation, animal feed, and other support activities.

Buyer Products:

  • Merial Group Ltd.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pfizer Inc. n/a 185,773.425 9.98 12.27 3.78 3.88 6.62
Johnson & Johnson n/a 181,816.951 17.62 15.46 3.28 2.98 15.54
Roche Holding Ltd. (ADR) n/a 152,846.074 23.37 19.55 4.38 3.77 6.56
GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Novartis AG (ADR) n/a 130,940.797 23.99 16.65 3.43 3.42 3.23
sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Genentech, Inc. n/a 81,094.091 33.82 28.67 8.00 6.85 9.67
AstraZeneca plc (ADR) n/a 77,549.535 12.55 12.58 2.84 2.73 8.20
Amgen, Inc. n/a 68,453.847 22.37 14.31 4.64 4.51 14.25
Eli Lilly & Co. n/a 65,456.964 28.01 16.98 4.04 3.68 7.18
Bristol Myers Squibb Co. n/a 60,537.680 38.78 21.16 3.42 3.01 16.56
Schering-Plough Corporation n/a 46,156.165 36.96 24.25 4.19 3.89 5.98
Alnylam Pharmaceuticals, Inc. n/a 634.071 n/a -10.80 22.30 20.99 3.37
Sangamo Biosciences, Inc. n/a 273.158 n/a -12.82 38.08 24.75 6.21
Novavax, Inc. n/a 196.858 n/a -6.70 48.65 38.83 3.71
Vical Incorporated n/a 195.559 n/a -5.49 18.84 18.49 1.96
AVANIR Pharmaceuticals n/a 136.747 n/a n/a 7.26 15.69 n/a
Inhibitex, Inc. n/a 40.764 n/a -12.09 34.35 14.67 0.75
Buyer
  Pfizer Inc. n/a 185,773.425 9.98 12.27 3.78 3.88 6.62
Johnson & Johnson n/a 181,816.951 17.62 15.46 3.28 2.98 15.54
Target
  Pfizer Inc. n/a 185,773.425 9.98 12.27 3.78 3.88 6.62
Johnson & Johnson n/a 181,816.951 17.62 15.46 3.28 2.98 15.54
Roche Holding Ltd. (ADR) n/a 152,846.074 23.37 19.55 4.38 3.77 6.56
GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Novartis AG (ADR) n/a 130,940.797 23.99 16.65 3.43 3.42 3.23

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Neurogen Corporation 100.00% 354.127 n/a -5.39 42.15 34.17 4.08
Sunesis Pharmaceuticals, Inc. 46.30% 125.004 n/a -3.33 9.52 9.81 2.58
Arena Pharmaceuticals, Inc. 39.50% 747.912 n/a -4.55 32.03 29.18 1.95
Rigel Pharmaceuticals, Inc. 23.70% 296.315 n/a -4.55 11.30 9.18 4.07
Vertex Pharmaceuticals Incorporated 16.80% 3,627.097 n/a -9.59 14.74 11.96 7.24
Alnylam Pharmaceuticals, Inc. 3.00% 634.071 n/a -10.80 22.30 20.99 3.37
deCODE genetics, Inc. 3.00% 238.784 n/a -2.59 6.13 5.57 n/a
Diversa Corporation 1.00% 253.435 n/a -9.10 4.97 4.84 7.26
Target
  Micromet Inc. 19.00% 82.856 n/a -2.53 3.16 5.32 26.73
Infinity Pharmaceuticals Inc. 18.00% 208.108 n/a -9.56 8.71 9.09 3.43
Critical Therapeutics, Inc. 10.00% 104.389 n/a -3.05 7.30 4.67 2.25
Option Care, Inc. 9.50% 535.901 22.65 20.26 0.75 0.66 16.40
Seattle Genetics, Inc. 9.30% 564.933 n/a -14.03 46.30 29.38 6.92
PDL BioPharma Inc. 8.00% 2,877.777 n/a 73.88 6.67 5.94 24.10
Abbott Laboratories n/a 84,288.496 54.40 19.28 3.73 3.72 n/a
Baxter International Inc. n/a 37,709.816 24.84 21.71 3.54 3.43 8.34
Cardinal Health, Inc. n/a 26,906.163 19.93 20.66 0.31 0.31 7.77
Becton, Dickinson and Co. n/a 18,677.709 24.39 20.13 3.11 2.96 5.58
Medarex, Inc. n/a 1,924.479 n/a -62.54 40.86 41.21 3.45
Human Genome Sciences n/a 1,365.526 n/a -5.98 48.47 26.89 7.89
Applix, Inc. n/a 255.585 25.58 40.35 4.48 3.79 12.00
Dyax Corp. n/a 223.889 n/a -3.64 17.58 13.74 10.98
Cerus Corporation n/a 196.206 n/a -5.07 5.90 11.01 2.07
SM&A n/a 131.566 33.71 17.50 1.69 1.44 4.31
Avalon Pharmaceuticals, Inc. n/a 65.589 n/a -2.92 22.49 19.33 2.88

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Bristol Myers Squibb Co. n/a 60,537.680 38.78 21.16 3.42 3.01 16.56
LG Philips LCD Co., Ltd. (ADR) n/a 17,196.624 n/a 59.45 1.47 1.36 2.42
AU Optronics Corp. (ADR) n/a 10,593.638 18.54 23.01 1.29 0.76 1.56
Sigma-Aldrich Corporation n/a 5,604.588 19.65 19.01 3.03 2.80 5.99
Biovail Corporation (USA) n/a 4,066.947 17.16 13.56 3.72 4.70 7.28
MGi Pharma, Inc. n/a 1,838.805 n/a 77.21 5.29 4.70 n/a
Metabasis Therapeutics, Inc. n/a 244.140 n/a -5.47 35.70 16.73 4.01
Theragenics Corporation n/a 144.683 19.94 n/a 2.53 n/a 1.92
Target
  AmerisourceBergen Corp. 29.00% 9,647.715 19.56 19.88 0.15 0.15 6.93
McKesson Corporation 18.00% 18,039.456 19.76 18.84 0.19 0.18 5.76
Cardinal Health, Inc. 15.00% 26,906.163 19.93 20.66 0.31 0.31 7.77
Abbott Laboratories 12.00% 84,288.496 54.40 19.28 3.73 3.72 n/a
GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Merck & Co., Inc. n/a 109,945.758 23.81 17.14 4.78 4.69 6.80
Medco Health Solutions Inc. n/a 22,523.128 26.18 23.05 0.52 0.49 n/a
Option Care, Inc. n/a 535.901 22.65 20.26 0.75 0.66 16.40
GTC Biotherapeutics, Inc. n/a 90.373 n/a -2.74 9.66 12.98 3.21
Government - United States n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Schering-Plough Corporation n/a 46,156.165 36.96 24.25 4.19 3.89 5.98
Crucell N.V. (ADR) n/a 1,323.323 n/a -32.79 12.95 4.36 3.46
Avalon Pharmaceuticals, Inc. n/a 65.589 n/a -2.92 22.49 19.33 2.88
CSL Limited n/a n/a n/a n/a n/a n/a n/a
Buyer
  sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
AstraZeneca plc (ADR) n/a 77,549.535 12.55 12.58 2.84 2.73 8.20
Target
  GlaxoSmithKline plc (ADR) n/a 150,489.154 14.15 13.27 3.32 3.23 14.40
Novartis AG (ADR) n/a 130,940.797 23.99 16.65 3.43 3.42 3.23
sanofi-aventis (ADR) n/a 113,703.100 20.78 11.45 2.82 2.92 n/a
Merck & Co., Inc. n/a 109,945.758 23.81 17.14 4.78 4.69 6.80
Abbott Laboratories n/a 84,288.496 54.40 19.28 3.73 3.72 n/a
Schering-Plough Corporation n/a 46,156.165 36.96 24.25 4.19 3.89 5.98
Baxter International Inc. n/a 37,709.816 24.84 21.71 3.54 3.43 8.34
Teva Pharmaceutical Industries Ltd (ADR) n/a 31,840.000 16.79 17.90 3.61 3.47 23.48
Cardinal Health, Inc. n/a 26,906.163 19.93 20.66 0.31 0.31 7.77
Medco Health Solutions Inc. n/a 22,523.128 26.18 23.05 0.52 0.49 n/a
Becton, Dickinson and Co. n/a 18,677.709 24.39 20.13 3.11 2.96 5.58
PDL BioPharma Inc. n/a 2,877.777 n/a 73.88 6.67 5.94 24.10
Medarex, Inc. n/a 1,924.479 n/a -62.54 40.86 41.21 3.45
Biosite Incorporated n/a 1,575.310 40.68 39.06 5.03 4.82 5.28
Human Genome Sciences n/a 1,365.526 n/a -5.98 48.47 26.89 7.89
Crucell N.V. (ADR) n/a 1,323.323 n/a -32.79 12.95 4.36 3.46
Seattle Genetics, Inc. n/a 564.933 n/a -14.03 46.30 29.38 6.92
Option Care, Inc. n/a 535.901 22.65 20.26 0.75 0.66 16.40

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 22,995.7 1,353.6 24,349.3
Other Revenue 0.0 0.0 0.0
Total Revenue 22,995.7 1,353.6 24,349.3
Cost of Revenue 6,184.2 320.1 6,504.3
SG&A Expense 8,252.4 476.4 8,728.8
Depreciation & Amortization 0.0 0.0 0.0
Research & Development 4,870.8 440.5 5,311.3
Interest Expense -2,872.7 0.0 -2,872.7
Other Operating Expense -108.7 13.6 -95.1
Unusual Expense (Income) 164.3 -48.5 115.8
Total Expenses 16,490.3 1,202.1 17,692.4
Operating Income 6,505.4 151.5 6,656.9
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 0.0 92.9 92.9
Other, Net 0.0 0.0 0.0
Income Before Taxes 6,505.4 244.4 6,749.8
Income Taxes 1,887.3 82.7 1,970.0
Income After Taxes 4,618.1 161.7 4,779.8
Net Income - Excl. Xord. Items 4,618.1 161.7 4,779.8
Net Income - Incl. Xord. Items 4,618.1 161.7 4,779.8
Income Avail. to Common 4,618.1 161.7 4,779.8
Share Items
Basic Avg. Shares Outstanding 2,166.1 237.9 2,404.0
Basic EPS - Excl. Xord. Items 2.13 0.68 1.99
Basic EPS - Incl. Xord. Items 2.13 0.68 1.99
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 2,180.0 241.4 2,421.4
F.D. EPS - Excl. Xord. Items 2.12 0.67 1.97
F.D. EPS - Incl. Xord. Items 2.12 0.67 1.97
Dividends Per Common Share 1.52 0.00 1.52
Balance Sheet
Assets
Cash and Equivalents 2,101.9 463.3 2,565.2
ST Investments 1,954.3 574.2 2,528.5
Accounts Receivable 4,016.2 280.6 4,296.8
Inventory 1,726.8 87.6 1,814.4
Prepayments and Advances 1,942.5 0.0 1,942.5
Other Current Assets 0.0 35.3 35.3
Current Assets 11,741.7 1,441.0 13,182.7
PPE 24,366.0 0.0 24,366.0
Accum D&A -11,426.2 0.0 -11,426.2
PPE, Net 12,939.8 502.8 13,442.6
Goodwill & Intangibles 2,318.7 190.4 2,509.1
Long Term Investments 7,839.1 566.4 8,405.5
Other Assets 0.0 0.0 0.0
Other LT Assets 8,153.2 332.9 8,486.1
Total Assets 42,992.5 3,033.5 46,026.0
Liabilities
Accounts Payable 430.3 45.1 475.4
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 5,229.7 185.3 5,415.0
ST Debt 930.7 0.0 930.7
Other (Current) Liabilities 1,270.6 131.8 1,402.4
Current Liab. 7,861.3 362.2 8,223.5
LT Debt 5,545.3 1,164.1 6,709.4
Total LT Debt 5,545.3 1,164.1 6,709.4
Minority Interest (BS) 2,435.2 0.0 2,435.2
Deferred Taxes 8,671.4 0.0 8,671.4
Other LT Liab. 0.0 42.8 42.8
Total Liabilities 24,513.2 1,569.1 26,082.3
Shareholders Equity
Common Stock 29.8 2.6 32.4
Additional Paid in Capital 7,221.3 2,713.7 9,935.0
Retained Earnings 40,054.8 -705.7 39,349.1
Treasure Stock -27,734.0 -540.5 -28,274.5
Other Equity -1,092.6 -5.7 -1,098.3
Total Equity 18,479.3 1,464.4 19,943.7
Total Liab. & Equity 42,992.5 3,033.5 46,026.0
Shares Outstanding 2,164.6 237.7 2,402.3
Cash Flow
Operating Cash Flow
CF Net Income 4,618.1 161.7 4,779.8
CF Depreciation 2,145.4 117.8 2,263.2
CF Deferred Taxes -289.1 -11.5 -300.6
Other Non-Cash Items -2,190.9 -26.8 -2,217.7
Change in Working Capital -154.0 -346.0 -500.0
Total Cash From Operating Activities 4,129.5 -104.8 4,024.7
Investing Cash Flow (not calculated)
Capital Expenditures -983.3 -145.6 -1,128.9
Other Investing Cash Flows -6,686.7 417.7 -6,269.0
Total Cash From Investing Activities -7,670.0 272.1 -7,397.9
Financing Cash Flow (not calculated)
Dividends Paid -3,319.4 0.0 -3,319.4
Purchase Or Sale of Stock -885.9 -179.8 -1,065.7
Purchase and Retirement of Debt -282.2 638.5 356.3
Other Financing Cash Flow -111.3 -310.6 -421.9
Total Cash From Financing Activities -4,598.8 148.1 -4,450.7
Exchange Rate Effects 54.0 -0.1 53.9
Net Change in Cash -8,085.3 315.3 -7,770.0
Cash Taxes Paid 2,400.0 2.0 2,402.0
Cash Interest Paid 342.1 3.8 345.9